FDA Approves Lucentis Biosimilar Nufymco - Scorecard - MDSpire

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

  • By

  • Conexiant News Staff

  • January 2, 2026

  • 1 min

Share

Clinical Scorecard: FDA Approves Lucentis Biosimilar Nufymco

At a Glance

CategoryDetail
ConditionWet Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema due to Retinal Vein Occlusion, Myopic Choroidal Neovascularization
Key MechanismsBiosimilar to ranibizumab, targeting vascular endothelial growth factor (VEGF)
Target PopulationPatients with wAMD, DME, DR, RVO, and mCNV
Care SettingOphthalmology

Key Highlights

  • Nufymco is a biosimilar of Lucentis (ranibizumab)
  • FDA approved for multiple ophthalmic conditions
  • Marketed in the US by Zydus Lifesciences Limited
  • Developed by Bioeq, a joint venture of Formycon AG and Polpharma Biologics Group
  • Aims to expand access to affordable treatment options

Guideline-Based Recommendations

Diagnosis

  • Evaluate patients for wAMD, DME, DR, RVO, and mCNV

Management

  • Consider Nufymco as a treatment option for approved conditions

Monitoring & Follow-up

  • Regular follow-up for treatment efficacy and adverse effects

Risks

  • Potential for adverse reactions similar to those of ranibizumab

Patient & Prescribing Data

Patients diagnosed with wet macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema due to retinal vein occlusion, or myopic choroidal neovascularization

Nufymco provides a biosimilar option to improve access to treatment

Clinical Best Practices

  • Ensure proper patient selection based on FDA-approved indications
  • Educate patients on the benefits and risks of biosimilar therapy
  • Monitor patients closely for response to treatment

Related Resources & Content

Original Source(s)

FDA Approves Lucentis Biosimilar Nufymco

  • by Conexiant News Staff

  • January 2, 2026

Related Content

Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.

Blindness Linked to Higher Loneliness Scores

Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.

ASRS President Reflects on a Year of Change

As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.